WHO CAN ENTER

Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars. Entry eligibility period of 1 August 2024-31 July 2025.

WHO CAN ENTER

Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics and biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business. Entry eligibility period of 1 August 2024-31 July 2025.

• Company of the Year – Americas
• Company of the Year – EMEA
• Company of the Year – Asia-Pacific

WHO CAN ENTER

Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products. Entry eligibility period of 1 August 2024-31 July 2025.

WHO CAN ENTER

Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight. Entry eligibility period of 1 August 2024-31 July 2025.

WHO CAN ENTER

Entries in this category could include known molecules that are repurposed for new indications, reformulated in a way that adds value for patients, put together in innovative combinations, or which feature added-value packaging or delivery methods. Entry eligibility period of 1 August 2024-31 July 2025.

WHO CAN ENTER

Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products. Entry eligibility period of 1 August 2024-31 July 2025.

WHO CAN ENTER

Open to any company supplying off-patent active pharmaceutical ingredients (APIs) or Intermediates. Entry eligibility period of 1 August 2024-31 July 2025.

WHO CAN ENTER

Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage. Entry eligibility period of 1 August 2024-31 July 2025.

WHO CAN ENTER

Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries. Entry eligibility period of 1 August 2024-31 July 2025.

WHO CAN ENTER

Humanitarian charity International Health Partners (IHP) has partnered with Generics Bulletin to create this Award. Entries could include: company approach to CSR, implementation, engagement plans, training & education programmes, compulsory licensing and humanitarian aid donations. Entry eligibility period of 1 August 2024-31 July 2025.

WHO CAN ENTER

Awarded to recognise outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract manufacturers, law firms and consultants. Entry eligibility period of 1 August 2024-31 July 2025.

WHO CAN ENTER

This category allows industry firms and organizations to highlight outstanding campaigns used to successfully promote and highlight generics, biosimilars and value-added medicines across the world. This could include awareness campaigns, efforts to highlight key industry contributions to a wider audience, or initiatives that raise the profile of off-patent medicines for healthcare industry stakeholders. Entry eligibility period of 1 August 2024-31 July 2025.